185 related articles for article (PubMed ID: 36803258)
1. Emerging treatment strategies in hepatobiliary cancer.
Guven DC; Yildirim HC; Chalabiyev E; Kus F; Yilmaz F; Yasar S; Akyildiz A; Aktas BY; Yalcin S; Dizdar O
Expert Rev Anticancer Ther; 2023 Mar; 23(3):243-256. PubMed ID: 36803258
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
4. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
Larsen FO; Markussen A; Diness LV; Nielsen D
Oncology; 2018; 94(1):19-24. PubMed ID: 28930749
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
7. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
[TBL] [Abstract][Full Text] [Related]
10. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with NAB
Woodford R; Brungs D; Leighton C; Grimison P; Sjoquist KM; Becker T; Robinson S; Gebski V; Wilson K; Chantrill L; Aghmesheh M
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e220-e226. PubMed ID: 34180586
[TBL] [Abstract][Full Text] [Related]
13. Systemic and targeted therapy for biliary tract tumors and primary liver tumors.
Thomas MB
Surg Oncol Clin N Am; 2014 Apr; 23(2):369-81. PubMed ID: 24560115
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of biliary tract cancers.
Uson Junior PLS; Bogenberger J; Borad MJ
Curr Opin Gastroenterol; 2020 Mar; 36(2):85-89. PubMed ID: 31972599
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
16. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Park K; Kim KP; Park S; Chang HM
Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy in treatments for biliary tract cancer.
Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
Akhoundova Sanoyan D; McNamara MG; Lamarca A; Valle JW
Curr Opin Oncol; 2020 Jul; 32(4):364-369. PubMed ID: 32541326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]